Skip to main content

Table 2 Pathogen Identification

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

ItemTotalIFNα1b GroupControl Group
Influenza virusa16 (9.94%)9 (11.84%)7 (8.24%)
Parainfluenza virus4 (2.48%)3 (3.95%)1 (1.18%)
Respiratory syncytial virus7 (4.35%)2 (2.63%)5 (5.88%)
Rhinovirus7 (4.35%)3 (3.95%)4 (4.71%)
Adenovirus7 (4.35%)5 (6.58%)2 (2.35%)
EB virus16 (9.94%)7 (9.21%)9 (10.59%)
Herpes virus14 (8.64%)8 (10.53%)6 (7.06%)
Coronavirus2 (1.24%)1 (1.32%)1 (1.18%)
Human metapneumovirus1 (0.62%)0 (0.00%)1 (1.18%)
Streptococcus pneumoniae2 (1.24%)2 (2.63%)0 (0.00%)
Mycoplasma10 (6.21%)4 (5.26%)6 (7.06%)
Chlamydia2 (1.24%)1 (1.32%)1 (1.18%)
Moraxella catarrhalis2 (1.24%)0 (0.00%)2 (2.35%)
Simple virus infection49 (30.43%)21 (27.63%)28 (32.94%)
Single virus infection30 (18.63%)9 (11.84%)21 (24.71%)
Two-virus infection9 (5.59%)7 (9.21%)2 (2.35%)
Multivirus infection10 (6.21%)5 (6.58%)5 (5.88%)
Mycoplasma + virus5 (3.11%)2 (2.63%)3 (3.53%)
Chlamydia + virus2 (1.24%)1 (1.32%)1 (1.18%)
  1. arepresents negative results from a rapid influenza antigen test during screening and positive results from an influenza virus nucleic acid test at the central laboratory. No anti-influenza drugs were given during clinical treatment.